• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol Methods . NUCLEOPROTEIN-BASED ELISA FOR DETECTION OF SARS-CoV-2 IgG ANTIBODIES: COULD AN OLD ASSAY BE SUITABLE FOR SERODIAGNOSIS OF THE NEW

tetano

Editor, Senior Moderator
J Virol Methods


. 2021 Jan 13;114064.
doi: 10.1016/j.jviromet.2021.114064. Online ahead of print.
NUCLEOPROTEIN-BASED ELISA FOR DETECTION OF SARS-CoV-2 IgG ANTIBODIES: COULD AN OLD ASSAY BE SUITABLE FOR SERODIAGNOSIS OF THE NEW CORONAVIRUS?


Tania Regina Tozetto-Mendoza[SUP] 1 [/SUP], Kelly Aparecida Kanunfre[SUP] 2 [/SUP], Lucy Santos Vilas-Boas[SUP] 3 [/SUP], Evelyn Patricia Sanchez Espinoza[SUP] 4 [/SUP], Heuder Gustavo Oliveira Pai?o[SUP] 5 [/SUP], Mussya Cisotto Rocha[SUP] 2 [/SUP], Anderson Vicente de Paula[SUP] 3 [/SUP], Maura Salaroli de Oliveira[SUP] 6 [/SUP], Daniella Bosco Zampelli[SUP] 7 [/SUP], Jos? Mauro Vieira Jr[SUP] 7 [/SUP], Lewis Buss[SUP] 8 [/SUP], Silvia Figueiredo Costa[SUP] 4 [/SUP], Ester Cerdeira Sabino[SUP] 9 [/SUP], Steven S Witkin[SUP] 10 [/SUP], Thelma Suely Okay[SUP] 11 [/SUP], Maria Cassia Mendes-Correa[SUP] 5 [/SUP]



Affiliations

Abstract

Objectives: We evaluated the performance of a nucleoprotein-based enzyme-linked immunosorbent assay (ELISA) for detection of IgG antibodies to SARS-CoV-2.
Methods: The ELISA was based on serum IgG reactivity to a 46-kDa protein derived from the recombinant SARS-CoV2 nucleoprotein. Assay sensitivity was assessed using serum samples from 134 COVID-19 confirmed cases obtained > 15 days after symptom onset. Specificity was determined by testing sera from 94 healthy controls. Cross-reactivity was evaluated with sera from 96 individuals with previous dengue or zika virus-confirmed infections, with 44 sera from individuals with confirmed infections to other respiratory viruses or with bacterial and fungal infections that cause pneumonia and with 40 sera negative for SARS-CoV-2 nucleoprotein by commercial ELISA kits.
Results: The majority of subjects were male and> 60 years old. Assay sensitivity was 90.3% (95% confidence interval 84.1% - 94.2%) and specificity was 97.9% (92.6% - 99.4%). There was no cross-reactivity with sera from individuals diagnosed with dengue, zika virus, influenza virus, rhinovirus, adenovirus, respiratory syncytial virus, seasonal coronavirus, Mycobacterium tuberculosis, Staphylococcus (S. aureus and coagulase-negative), Streptococcus pneumoniae, Klebsiella pneumoniae and the fungus Aspergillus fumigatus. The level of concordance of our test with results from commercial ELISA kits was 100%.
Conclusion: The nucleoprotein-based ELISA was specific for detection of IgG anti-nucleoprotein antibodies to SARS-CoV-2.. It utilizes a frequently employed low expense assay protocol and is easier to perform than other currently available commercial SARS-CoV2 antibody detection tests.

Keywords: COVID-19; ELISA; IgG antibody; Nucleoprotein antigen; SARS-CoV-2.
 
Back
Top Bottom